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Abstract
Obtaining informed consent is a great challenge in global health research. There is a need
for tools that can screen for and improve potential research participants’ understanding of
the research study at the time of recruitment. Limited empirical research has been con-
ducted in low and middle income countries, evaluating informed consent processes in geno-
mics research. We sought to investigate the quality of informed consent obtained in a South
African psychiatric genomics study. A Xhosa language version of the University of Califor-
nia, San Diego Brief Assessment of Capacity to Consent Questionnaire (UBACC) was used
to screen for capacity to consent and improve understanding through iterative learning in a
sample of 528 Xhosa people with schizophrenia and 528 controls. We address two ques-
tions: firstly, whether research participants’ understanding of the research study improved
through iterative learning; and secondly, what were predictors for better understanding of
the research study at the initial screening? During screening 290 (55%) cases and 172
(33%) controls scored below the 14.5 cut-off for acceptable understanding of the research
study elements, however after iterative learning only 38 (7%) cases and 13 (2.5%) controls
continued to score below this cut-off. Significant variables associated with increased under-
standing of the consent included the psychiatric nurse recruiter conducting the consent
screening, higher participant level of education, and being a control. The UBACC proved an
effective tool to improve understanding of research study elements during consent, for both
cases and controls. The tool holds utility for complex studies such as those involving geno-
mics, where iterative learning can be used to make significant improvements in understand-
ing of research study elements. The UBACC may be particularly important in groups with
severe mental illness and lower education levels. Study recruiters play a significant role in
managing the quality of the informed consent process.
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Introduction
Obtaining informed consent is a great challenge in global health research. The understanding
of research study elements, such as the purpose of the research, risks and benefits of participa-
tion and the research design, varies considerably amongst participants in both high-income
countries (HICs) and low-middle income countries (LMICs) [1]. A recent meta-analysis of
informed consent comprehension in health research conducted in Sub-Saharan Africa indi-
cates that only 65% of participants generally understand the purpose of a research study, and
only 51% appreciate the risks of participation [2]. There is a need for tools that can screen for
and improve potential research participants’ understanding of the research study at the time of
recruitment. However, limited empirical research has been conducted in LMICs on evaluating
informed consent processes. Available studies indicate that low literacy levels and lengthy
informed consent materials complicate the informed consent process, particularly when draw-
ing from complex medical terminology that is incongruent with local cultural idioms and
expressions [2, 3]. Many participants also tend to be unfamiliar with the research process, and
power dynamics between recruiting clinicians and potential research participants may influ-
ence the voluntariness of participation [1, 2, 4]. In the context of these challenges we sought to
investigate the quality of informed consent obtained during the course of a South African psy-
chiatric genomics study, by examining whether participants’ understanding was improved by
iterative learning during recruitment, as well as factors that influenced participants’
understanding.
Studies in HICs show that understanding of informed consent materials can be improved
through an iterative learning process of firstly presenting the study information, secondly
assessing a participant’s understanding of the study elements, and finally revisiting and revis-
ing poorly understood elements [5–7]. Participant understanding has been shown to be reli-
ably assessed using the University of California, San Diego Brief Assessment of Capacity to
Consent Questionnaire (UBACC), which was originally developed as a 10-item screening tool
for decisional capacity in participants being recruited for schizophrenia research [8]. The tool
may, however, have broader applicability in global health research. The UBACC screens for
participants’ appreciation and understanding of key research study elements including the
purpose of the study, protocol procedures, study risks and benefits, and the voluntary nature
of participation [8]. In addition to schizophrenia research [9] the UBACC has been used as a
screening tool for decisional capacity in neurocognitive [10–12] and HIV [13] research. To the
authors’ knowledge, however, the UBACC has yet to be used in LMICs.
We used the UBACC as a screening and education tool during recruitment of cases and
controls for the Genomics of Schizophrenia in South African Xhosa People (SAX) project. We
address two questions: firstly, whether research participants’ understanding of the research
study improved through iterative learning conducted after screening at the time of recruit-
ment; and secondly, what were predictors for better understanding of the research study at the
initial screening?
Methods
Genomics of schizophrenia in South African Xhosa People (SAX)
African populations are currently under-represented in psychiatric genomics research [14].
The SAX project aims to contribute to filling this gap by identifying mutations underlying pre-
disposition to schizophrenia in the Xhosa people. Schizophrenia is characterized by a range of
cognitive, behavioral and emotional dysfunctions and by impaired occupational and social
functioning [15]. These impairments could have implications for decisional capacity in
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consenting to participate in research. Studies in HICs indicate that decisional capacity varies
considerably across people with schizophrenia, influenced most significantly by the neurocog-
nitive impairments associated with the disorder [16–18]. The SAX study provided a unique
opportunity to study the consent process in a LMIC, both among people with severe mental ill-
ness (cases) and among people presenting for treatment for other health-related problems
(controls).
SAX cases are recruited from provincial psychiatric hospitals and clinics in the Eastern and
Western Cape provinces of South Africa, and include those who have fulfilled the diagnostic
criteria for schizophrenia or schizoaffective disorder over at least a two-year period. SAX con-
trols include Xhosa people who present for treatment of other medical conditions at univer-
sity-affiliated general medical hospitals and community health centers that draw from similar
catchment areas to the psychiatric hospitals. Exclusion criteria for controls include a previous
history of psychosis, pre-existing neurological conditions such as brain injury or epilepsy, or
patients presenting for treatment of injuries related to substance use.
All participants recruited for the SAX study complete the Structured Diagnostic Interview
for DSM-IV Axis I Disorders (SCID-I) [19], along with other psychiatric rating scales, and
provide blood samples for DNA and HIV testing. All clinical interview materials are adminis-
tered in Xhosa, having been translated in accordance with the World Health Organization
(WHO) translation guidelines [20]. This process includes both forward and back-translation
of the tools, as well as a committee approach of discussion and debate about challenging con-
cepts and constructs to select the most linguistically and conceptually appropriate Xhosa ter-
minology. However, in some instances no direct Xhosa translation is available, particularly for
the more complex genomics terminology, and translations then focused on developing phrases
or Xhosa terminology that captured the conceptual explanation of these English terms. Essen-
tially translators are developing a discourse for neurogenetic concepts in the Xhosa language.
Participants complete the UBACC during the informed consent process. This procedure,
described under data collection, assists us in identifying SAX study elements that require fur-
ther explanation. Participants then engage in an iterative learning process of corrective feed-
back and repetition of information to improve understanding of these elements.
This research was approved by the University of Cape Town, Health Sciences Research Eth-
ics Committee, Rhodes University Ethics Standards Committee, Walter Sisulu University, Fac-
ulty of Health Sciences Research Ethics Committee, Columbia University Institutional Review
Board and University of Washington Human Subjects Division.
Hypotheses
While studies have established that people with schizophrenia will likely struggle more with
informed consent understanding than healthy controls [16–18], work within LMICs highlights
the influence of poor literacy and unfamiliarity with the research process as additional factors
that impact on the informed consent process [2–4]. The lack of local language terms to further
support the explanation of genomics terminology is an additional barrier. We therefore antici-
pated that both cases and controls would struggle with some of the terminology and concepts in
the SAX protocol such as genetics, DNA, sample storage and cell immortalization. This may
compromise understanding of key SAX study elements such as the purpose of the research, risks
and benefits of participation and the research design. We hypothesized that an iterative learning
approach, using the UBACC would improve understanding among both cases and controls.
Second, previous studies identified schizophrenia diagnosis and neuro-cognitive impair-
ments as predictors of poor decisional capacity [16, 17]. We hypothesized that being a case or
control, levels of education and global functioning scores on the Global Assessment of
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Functioning (GAF) scale [21], would be associated with understanding of SAX study elements
during initial screening with the UBACC. We were also interested in associations between the
SAX recruiters, the region within which participants were recruited from as well as sex and age
demographics, and understanding of the SAX study element.
Data collection
During recruitment, all SAX participants receive information about the SAX study aims, meth-
ods, risks and benefits of participating, and expected outcomes in the form of an information
sheet written in Xhosa. This material is read and explained to each participant by one of five
first language Xhosa speaking SAX psychiatric nurse recruiters, with special focus on complex
terms such as genetics, DNA, sample storage and cell immortalization. For the purposes of this
study we then ask participants to complete the UBACC as a screening of their initial under-
standing of the study. Individual UBACC items that are incorrectly answered are flagged for
follow-up with the participant. The recruiter then immediately revisits the SAX study elements
related to those items, corrects the participant’s misunderstanding and repeats important
information about that study element, often by rephrasing the material. The incorrect UBACC
items are re-administered during a second UBACC administration. Participants achieving a
total score of above 14.5 demonstrate sufficient understanding of the study elements to indi-
cate capacity to consent [8]. Participants who continue to score below this cut-off after the sec-
ond UBACC administration receive additional corrective feedback and information until the
cut-off score is achieved, or a total of 4 administrations of the UBACC are completed. This
process takes between 15–30 minutes. Participants who continue to score below the 14.5 cut-
off are then removed from the study.
Participants recruited for the SAX study from March 2015 to November 2016 were
included for analysis. Cases and controls were matched to sex, age, education level and region
recruited from. To achieve a power of 0.9 at a significance of 0.05 we required a sample size of
at least 181 matched pairs. The initial UBACC screening scores and scores obtained after an
iterative learning process were recorded, along with the Global Assessment of Functioning
(GAF) score and the following participant information: diagnosis, gender, age group, educa-
tion level, region recruited from, and the psychiatric nurse doing the recruiting.
Measures
The University of California, San Diego Brief Assessment of Capacity to Consent Ques-
tionnaire (UBACC). The 10-item UBACC questionnaire was translated into Xhosa and then
adapted for the SAX study, including one change. Item 10 of the original UBACC (“Who will
pay for your medical care if you are injured as a direct result of participating in this study?”)
was not applicable because the SAX study was an exploratory study that provided little risk of
injury to participants. This item was replaced with a question about cell line immortalization
which was a key aspect of the SAX study (“Do you have to agree to store your cells?”). A sum-
mary of the original UBACC English version, the translated and adapted SAX Xhosa version
and English back translation of the tool are summarized in Table 1. Each item is scored on a
scale of 0 (incorrect), 1 (some understanding) or 2 (full understanding); with a maximum
score of 2 for each item(total scores therefore ranging from 0 to 20).
Global Assessment of Functioning (GAF) scale. The GAF scale is a standardized method
of assessing the severity of psychiatric illness against overall level of functioning (on a scale of
0–100) [21]. While this measure is typically used in psychiatric populations, we included GAF
scores for our controls as mental and substance use disorders are commonly reported amongst
people presenting with health complaints.
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Additional participant information. The following categorical variables were assigned to
participants: diagnosis (cases–diagnosis of schizophrenia or schizoaffective disorder; or con-
trol), gender (male or female), age group (20–39 years or 40–59 years), education level (pri-
mary school–achieved Grade 7 or less; secondary school–achieved Grade 8 or more), region
recruited from (Eastern Cape or Western Cape). Dummy codes were developed for each psy-
chiatric nurse recruiter (A-E). The recruiter (A) with the lowest UBACC screening scores was
assigned as the reference nurse against which the other four nurses were compared.
Data analysis
A repeated measures t-test was used to compare performance on the UBACC across trials 1
(screening) and 2 (after iterative learning) in our cases and controls respectively. Linear regres-
sion methods were used to identify hypothesized predictors of decisional capacity during
screening with the UBACC. The following variables were included in the model for analysis:
UBACC scores from trial 1; GAF scores; participant being a case versus a control; sex; age
group; education level; region recruited from; and psychiatric nurse conducting the recruit-
ment interview. Statistical significance levels for both analyses were set at 5%, and data analysis
was generated and managed using SPSS.
Table 1. The forward- and back-translation of the UBACC.
Original UBACC English version UBACC Xhosa version UBACC English back-translation
1. What is the purpose of the study that was
just described to you?
1. Yintoni injongo yoluphondo lwenzziwayo
ndigqiba ukukucacisela ngalo?
1. What is the purpose of the investigation that I have
just explained to you?
2. What makes you want to consider
participating in this study?
2. Yintoni ekwenze ukuba ufune ukuthabatha
inxaxheba koluphando?
2. What made you want to take part in this
investigation?
3. Do you believe this is primarily research or
primarily treatment?
3. Ingaba ucinga ukuba olu luphando okanye
lunyango?
3. Do you think this is an investigation or treatment?
4. Do you have to be in this study if you do
not want to participate?
4. Ucinga ukuba kunyanzelekile na ukuba ube
koluphando nokuba awufuni?
4. Do you think you must take part in this investigation
even if you don’t want to?
5. If you withdraw from the study, will you still
be able to receive regular treatment?
5. Ucinga ukuba uye wayeka ukuthabatha
inxaxheba koluphando ungakwazi ukufumana
unyango lwakho njengesiqhelo?
5. Do you think if you stop participating in this
investigation you won’t be able to get your treatment
as usual?
6. If you participate in this study, what are
some of the things that you will be asked to
do?
6. Ukuba uthe wathatha inxaxheba koluphando
zeziphi ezinye zezinto ozakucelwa uzenze?
6. If you are taking part in this investigation what are
the things that you will be asked to do?
7. Please describe some of the risks or
discomforts that people may experience if
they participate in this study
7. Ndicela uchaze ubungozi okanye ubunzima
onokubufumana ukuba uthe wathatha inxaxheba
koluphando?
7. Can you please explain some of the dangers, risks,
harms or difficulties you may come across if you take
part in this investigation?
8. Please describe some of the possible
benefits of this study
8. Ndicela uchaze inzuzo/amanye amancedo
anokufumaneka koluphando?
8. Can you explain the benefits, advice, help or other
services you will get from this investigation?
9. Is it possible that being in this study will not
have any benefit to you?
9. Ingaba igenzeka into yokuba oluphando
lungangabi luncedo kuwe?
9. Do you think that the investigation may not help
you?
10. Who will pay for your medical care if you
are injured as a direct result of participating
in this study?
Replaced with: Do you have to agree to store
your cells?
10. Ingaba kunyanzelekile ukuba imisebe yakho
yegazi iyokugcinwa?
10. Do you have to agree to store your cells?
https://doi.org/10.1371/journal.pone.0188466.t001
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Results
A total of 1056 participants, or 528 matched pairs of cases and controls were included for anal-
ysis. Sample information is summarized in Table 2.
Results from the repeated measures t-test, are presented in Table 3 and Fig 1. Both cases
and controls achieved large and significant improvements in UBACC scores following iterative
learning. Importantly, 290 (55%) cases and 172 (33%) controls scored below the 14.5 cut-off
for acceptable understanding of the research study elements during screening, and without
iterative learning would have been excluded from the study. After iterative learning, however,
only 38 (7%) cases and 13 (2.5%) continued to score below this cut-off after the second
UBACC trial. These participants engaged in further iterative learning and up to two additional
UBACC trials, following which all achieved above the 14.5 cut-off score and were recruited for
the study.
Results from the linear regression, summarized in Table 4, demonstrated large significant
associations between understanding of SAX study elements during screening, and i) partici-
pants without a diagnosis of schizophrenia, ii) those with a higher level of education, and iii)
specific psychiatric nurse recruiters explaining the study. Being female, and of younger age
predicted better understanding as did higher GAF scores, whilst the region participants were
recruited from was not significant.
Discussion
Three key points emerge from these results. First, congruent with existing literature from
HICs [5, 17] our findings support the growing evidence demonstrating the ability to improve
decisional capacity through an iterative learning process using the UBACC. The UBACC
Table 2. Sample information.
Variables Categories/Labels Frequencies (%)
Diagnosis: Case 528 (50%)
Control 528 (50%)
Sex: Male 946 (89.6%)
Female 110 (10.4%)
Age group: Younger (20–39) 674 (63.8%)
Older (40–59) 382 (36.2%)
Education level: Primary (Grade 7) 336 (31.8%)
Secondary (Grade 8) 720 (68.2%)
Region recruited from: Western Cape 276 (26.1%)
Eastern Cape 780 (73.9%)






Table 3. Comparison of UBACC mean scores for cases and controls across UBACC trials 1 and 2.
Trial 1 M(SD) Trial 2
M(SD)
Mean difference Correlation P-value Effect size
Cases 13.66 (3.5) 17.69 (2.1) 4.03 (2.5) 0.700 <0.000 1.240
Controls 15.41 (3.0) 18.59 (1.7) 3.18 (2.2) 0.695 <0.000 1.128
https://doi.org/10.1371/journal.pone.0188466.t003
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proved an effective tool for improving understanding of SAX research study elements during
recruitment of both cases and controls in our LMIC setting. This appeared to be the case
despite the inherent challenges with low literacy, poor education and complex research study
terminology that were often not supported in the local language [2, 3]. The UBACC assisted
study recruiters in determining how much of the SAX protocol was understood by participants
after an initial introduction to the material, and who would particularly benefit from iterative
Fig 1. Changes in UBACC means across trials 1 and 2.
https://doi.org/10.1371/journal.pone.0188466.g001
Table 4. Linear regression analysis of hypothesized predictors of decisional capacity using the UBACC.
Model Unstandardized co-efficient Beta Std. Error P-value CI:95%
Constant 10.345 0.494 <0.000 9.376–11.314
Diagnosis (Cases*/Controls) 1.541 0.199 <0.000 1.151–1.931
GAF score 0.027 0.007 <0.000 0.014–0.040
Sex (Male*/Female) 0.643 0.293 0.028 0.069–1.218
Age (Younger/Older*) 0.710 0.189 <0.000 0.338–1.082
Education (Primary*/Secondary) 1.372 0.194 <0.000 0.992–1.752
Region (WC*/EC) 0.186 0.206 0.368 -0.219–0.590
Psychiatric nurse recruiter (A*) B 2.403 0.235 <0.000 1.942–2.864
C 2.426 0.262 <0.000 1.911–2.941
D 3.405 0.327 <0.000 2.762–4.047
E 1.628 0.301 <0.000 1.038–2.218
* Reference Group
https://doi.org/10.1371/journal.pone.0188466.t004
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learning. It also allowed recruiters to identify challenging elements of the SAX study, and
through iterative learning, improve understanding of these elements. This informed consent
process holds valuable utility for other psychiatric genomics studies in LMICs and African set-
tings. However, improvements in quality of understanding during consent may have wider
implications, one being the influence on recruitment rates. Improved understanding of the
field of genomics and how participating in such research may benefit society in the longer
term may result in an increased willingness on behalf of individuals to enroll on a study.
Although greater understanding of the study risks or limited direct benefits to communities in
the shorter term may have the opposite outcome with more individuals choosing not to partic-
ipate in a study.
Second, improvements in quality of understanding during consent in our control group
suggest that the UBACC and iterative learning may be helpful in other genomics studies and
the UBACC hassubsequently been incorporated as a recommended tool for evaluating quality
of consent in the Human Heredity and Health Consortium (H3Africa) Revised Guidelines for
Informed Consent [22]. People with severe mental illness are typically classified as a vulnerable
group for research. Yet many LMICs contend with poverty, challenges in access to education
and healthcare that create their own layers of vulnerability. There is a need for standardized
informed consent screening tools that can be used on site, during recruitment to improve
quality of consent. Such tools need to be easily adaptable to the diverse cultural and language
needs of LMIC research settings [2]. The UBACC appears particularly useful in this regard
because questionnaire items are adapted to the specific research study underway, allowing for
cultural and language translation to be performed concurrently.
Third a diagnosis of schizophrenia and low education level were strong predictors of poorer
understandings of SAX study elements initially, and to a lesser extent lower GAF scores and
older age. Such participants are likely to require more time and resources during recruitment.
However, the individual characteristics of study recruiters proved to be the largest predictor of
participants’ understanding of SAX study elements, a finding that is consistent with other
studies in LMICs [2, 4]. The understanding the recruiter holds about the study elements, their
ability to improvise and simplify explanations and the clarity with which they are able to
explain this information to participants, often moving between English and the local language
in doing so, likely has an important impact on the quality of informed consent. Adequate and
continued training of recruitment staff about the research study elements, informed consent
procedures and consistency in evaluating these elements using the UBACC is clearly of value.
Limitations
Several limitations of the current analysis and outcomes should be highlighted. First, our sam-
ple, while representative of the larger SAX sample, comprised mostly male participants (90%)
and did not adequately represent Xhosa women with schizophrenia. One explanation for this
may be that our recruitment strategy focused on participants from state psychiatric hospitals
and clinics where majority of the patients with a diagnosis of schizophrenia were men. Second,
the translation of psychometric instruments across different languages and cultural contexts,
and achieving linguistic and conceptual equivalence across English and Xhosa language ver-
sions of psychiatric tools holds many challenges [23, 24]. The lack of specific Xhosa terminol-
ogy for genomics language means that translators are developing this discourse as studies are
implemented in African settings. This may result is confusion and misunderstanding, which
will impact on the quality of understanding and informed consent. Regular revising of in-
formed consent materials and specifically the information sheet distributed to recruited partic-
ipants is an important contingency measure. Third, the specific characteristics, temperament,
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and communicative skills of individual recruiters are likely to have impacted on UBACC
scores e.g. some may have been more meticulous, knowledgable and provided explanations
about the SAX study materials in more accessible ways than others (though such variables are
difficult to quantify accurately). Finally, with respect to predictors of understanding during
screening, confounding variables such as neuro-cognitive impairment were not taken into
account during analysis.
Conclusion
Our analysis indicates that the UBACC is an effective tool for improving understanding of
research study elements during recruitment in a LMIC setting. Improved understanding was
evident both among cases and controls. The UBACC holds valuable potential utility in global
health research, and particularly for improving understanding during informed consent pro-
cesses in LMIC health research. This is particularly so for participants with severe mental ill-
ness, and those with low education levels. Finally, the study recruiters play a significant role in
managing the quality of the informed consent process.
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